Physician profile
Robert A Honkanen
NPI 1649212911
$5,219.26
in general payments reported to CMS, 2019-2025
24 companies · $1,045 in 2025
The $1,045 reported for 2025 was more than what 78% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $660 · 2020: $187 · 2021: $302 · 2022: $650 · 2023: $1,298 · 2024: $1,077 · 2025: $1,045.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,394 · Education: $26.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,394.19 |
| Education | $26.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,395.37 | 2019-2025 | Clareon, Rocklatan, Argos |
| Abbvie INC. | $1,125.03 | 2022-2025 | |
| Allergan, INC. | $518.51 | 2019-2022 | |
| Oyster Point Pharma, INC. | $442.65 | 2022-2025 | Tyrvaya, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $273.47 | 2019-2023 | |
| New World Medical,INC. | $210.21 | 2019-2025 | Ahmed Glaucoma Valve, Kahook Dual Blade, Streamline |
| Sight Sciences, INC. | $169.50 | 2022-2024 | Tearcare System, Omni Surgical System |
| Mallinckrodt Hospital Products INC. | $164.94 | 2022-2023 | Acthar |
| Aerie Pharmaceuticals, INC. | $149.20 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $118.25 | 2020-2024 | Cequa |
| Kowa Research Institute, INC. | $106.37 | 2023 | |
| Harrow Eye, LLC | $84.06 | 2024-2025 | Vevye |
| Dompe US, INC. | $69.46 | 2024-2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $69.02 | 2024 | Xdemvy |
| Biotissue Holdings INC. | $57.23 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $53.67 | 2021-2022 | |
| Bausch & Lomb Americas INC. | $48.42 | 2022-2023 | Miebo, Lotemax Sm, Vyzulta |
| Shire North American Group INC | $37.33 | 2019 | |
| Ocular Therapeutix, INC. | $31.47 | 2024-2025 | Dextenza |
| Surgical Specialties Corporation (US), INC. (Dba Corza Medical) | $24.44 | 2024 | |
| Glaukos Corporation | $20.94 | 2025 | Photrexa Viscous and Photrexa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $20.00 | 2021 | |
| Eyevance Pharmaceuticals LLC | $15.27 | 2021 | |
| Omeros Corporation | $14.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Honkanen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.